# SAB Biotherapeutics, Inc.: Form 8-K, filed Feb 2, 2024

- Company: [SAB Biotherapeutics, Inc.](/companies/sabs.md) (CIK 1833214)
- Form: 8-K
- Filed: 2024-02-02
- Accepted by EDGAR: Feb 2, 2024, 12:53 ET
- Period: 2024-01-30
- Accession: 0000950170-24-010093
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/sabs-20240130.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/

## Items reported

- Item 5.02: Departure or appointment of officers or directors
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/sabs-20240130.htm

Filed Feb 2, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-010093. Last ingested by Listed: Oct 24, 2026, 14:57 ET. No prices; not investment advice.